Claim OwnershipAUAUniversity
Subscribed: 73Played: 2,990
Subscribe
© All rights reserved
Description
The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
411 Episodes
Reverse
AUA2025: Key Takeaways: BPH
Presenters: Bilal Chughtai, MD & Dean S. Elterman, MD, MSc, FRCSC
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction
Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS
AUA Guidelines: Recurrent Uncomplicated Urinary Tract Infections in Women
Co-Hosts: A. Lenore Ackerman, MD, PhD & Melissa R. Kaufman, MD, PhD
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)
Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004723
Anorectal Malformation
AUA Urology Core Curriculum: auau.auanet.org/core
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guests: Christina Ho, MD and Molly E. Fuchs, MD
Outline:
Segment 1: Anorectal Malformation Overview/Background
Segment 2: Initial Evaluation and Management
Segment 3: Cloacal Malformations
Segment 4: Long-Term Bladder Management & Concern for CKD
Segment 5: Other Considerations
AUA2025: Key Takeaways: Endourology/Stones Highlights
Presenters: Davis Viprakasit, MD & Stephen Nakada MD, FACS, FRCS
Update Series (2025) Lesson 30: Beyond Ureteropelvic Junction: Case-Based Tips and Tricks in Robotic Ureteral Stricture Reconstructive Surgery
Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25
The Latest Breakthroughs in LG-IR-NMIBC (2025)
CME Available: auau.auanet.org/node/43689
After participating in this CME activity, participants will be able to:
1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.
2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.
3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.
4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).
5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.
6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
UroGen Pharma, Inc.
The Latest Breakthroughs in mHSPC
CME Available: https://auau.auanet.org/node/43825
After participating in this CME activity, participants will be able to:
1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.
2.Implement current clinical guidelines for biomarker testing in mHSPC.
3.Explain the role of the PI3K/AKT pathway in prostate cancer biology.
4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.
5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.
Acknowledgements:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
AUA2025: Key Takeaways: Sexual Dysfunction Highlights
Presenter: Brittany Berk, MD & Arthur Burnett, MD, MBA
AUA2025: Key Takeaways: Female Urology Highlights
Presenter: Mitch G. Goldenberg, MD & Kathleen Kobashi, MD, MBA, FACS
AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities
Presenter: Rosalyn M. Adam, PhD
AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted?
Presenter: Vin Gupta, MD, MPA
AUA2025: John K Lattimer Lecture: Telesurgery
Presenter: Vipul Patel, MD
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
CME Available: auau.auanet.org/node/42040
After participating in this CME activity, participants will be able to:
1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.
2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.
3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.
4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.
5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.
Acknowledgements
Support provided by an independent educational grant from:
Astellas and Pfizer, Inc.
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
CME Available: https://auau.auanet.org/node/43009
At the conclusion of this activity, participants will be able to:
1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.
4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.
5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Update Series (2025) Lesson 18: Multidisciplinary Evaluation and Management of Pelvic Pain in Women
Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25
AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice
CME Available: https://auau.auanet.org/node/43029
At the conclusion of this activity, participants will be able to:
1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer
2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation
3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer
4. Discern the different prognostic endpoints provided by various genomic tests
5. Recognize candidates for, and implications of, germline testing for prostate cancer.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems
CME Available: https://auau.auanet.org/node/43047
At the conclusion of this activity, participants will be able to:
1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills.
2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage.
3. Identify methods to treat significant toxicities from various intravesical therapies.
4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.
ACKNOWLEDGEMENTS:
This educational activity is supported by an independent educational grants from:
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The Surgical Management of BPH (2025)
CME Available: https://auau.auanet.org/node/43193
Acknowledgements: This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.
After participating in this CME activity, participants will be able to:
1. Utilize the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.
2. Determine the appropriate role and clinical expectation for current technologies, including pivotal studies, based on evidence.
3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.
4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.
AUA2025: AUA Advanced Prostate Cancer Course
CME Available: https://auau.auanet.org/node/43035
At the conclusion of this activity, participants will be able to:
1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling.
2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations.
3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC.
4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines.
5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Comments
Download from Google Play
Download from App Store
United States